The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
Histoindex Pte Ltd. launched its laboratory-developed test for metabolic dysfunction-associated steatohepatitis (MASH), ...
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
17d
AZoLifeSciences on MSNStudy Explores the Physiological Role of Nwd1 Gene in MASH PathogenesisMetabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.
Metabolic dysfunction-associated steatohepatitis (MASH ... A key factor in the pathology of MASH is the disruption of endoplasmic reticulum (ER) homeostasis. The ER stores calcium ions (Ca ...
Impaired lysosomal function (breaking down waste) leads to accumulation of excess lipids in liver cells, worsening NAFLD and contributing to its progression. By analyzing a clinical gene-profiling ...
“The data presented in this publication, both conventional and AI-assisted histology, suggest improvements in fibrosis in patients treated with icosabutate,” said Arun Sanyal, M.D., Director ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results